NASDAQ:MYL - Mylan Stock Price, Forecast & News

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Mylan NV (NASDAQ:MYL) released its earnings results on Thursday, February, 27th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.28 by $0.12. The business had revenue of $3.19 billion for the quarter, compared to analysts' expectations of $3.22 billion. Mylan had a net margin of 0.42% and a return on equity of 18.80%. The company's quarterly revenue was up 3.7% on a year-over-year basis. During the same period last year, the company earned $1.30 earnings per share. View Mylan's Earnings History.

Mylan is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Mylan.

Mylan updated its FY 2020 After-Hours earnings guidance on Thursday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.5-12.5 billion, compared to the consensus revenue estimate of $11.92 billion.

18 brokers have issued 12 month target prices for Mylan's stock. Their forecasts range from $18.00 to $36.00. On average, they expect Mylan's stock price to reach $26.09 in the next year. This suggests a possible upside of 51.8% from the stock's current price. View Analyst Price Targets for Mylan.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan.

Headlines about MYL stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mylan earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Mylan.

Mylan saw a increase in short interest in February. As of February 14th, there was short interest totalling 24,030,000 shares, an increase of 7.9% from the January 30th total of 22,280,000 shares. Based on an average daily trading volume, of 6,230,000 shares, the short-interest ratio is presently 3.9 days. Currently, 4.7% of the company's shares are sold short. View Mylan's Current Options Chain.

Some companies that are related to Mylan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Perrigo (PRGO), The Medicines (MDCO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mylan investors own include Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Allergan (AGN), Micron Technology (MU), Starbucks (SBUX), Netflix (NFLX), NVIDIA (NVDA), Intel (INTC) and General Electric (GE).

Mylan's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.53%), Pzena Investment Management LLC (4.03%), Geode Capital Management LLC (1.99%), AQR Capital Management LLC (1.80%), FIL Ltd (1.58%) and Bank of New York Mellon Corp (0.97%). Company insiders that own Mylan stock include Anthony Mauro, Goulds Bruce, Melina E Higgins, Paul Campbell, Rajiv Malik, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View Institutional Ownership Trends for Mylan.

MYL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Phoenix Holdings Ltd., Banco Santander S.A., Schroder Investment Management Group, First Trust Advisors LP, Bank of New York Mellon Corp, Amundi Pioneer Asset Management Inc. and FMR LLC. View Insider Buying and Selling for Mylan.

MYL stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Jacobs Levy Equity Management Inc., Pzena Investment Management LLC, Samlyn Capital LLC, Marshall Wace North America L.P., Marshall Wace LLP, FIL Ltd and Schonfeld Strategic Advisors LLC. Company insiders that have bought Mylan stock in the last two years include Melina E Higgins, Richard A Mark, Robert J Coury and Sjoerd S Vollebregt. View Insider Buying and Selling for Mylan.

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYL stock can currently be purchased for approximately $17.19.

Mylan has a market capitalization of $8.87 billion and generates $11.43 billion in revenue each year. The company earns $352.50 million in net income (profit) each year or $4.58 on an earnings per share basis. Mylan employs 35,000 workers across the globe.View Additional Information About Mylan.

The official website for Mylan is http://www.mylan.com/.

Mylan's mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company can be reached via phone at 724-514-1800 or via email at [email protected]